Protocol Ledger

NCT03887455 · Phase III · ACTIVE NOT RECRUITING

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Interventional Phase III clinical trial protocol NCT03887455 sponsored by Eisai in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-27 Enrollment: 1,906 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03887455
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,906 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03887455
Protocol FieldVerified Registry Value
NCT IdentifierNCT03887455
Consolidated Lead SponsorEisai
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1,906 participants (ACTUAL)
Registered Start Date2019-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI